Zobrazeno 1 - 10
of 393
pro vyhledávání: '"Edward K Geissler"'
Autor:
Gunther Glehr, Paloma Riquelme, Katharina Kronenberg, Robert Lohmayer, Víctor J. López-Madrona, Michael Kapinsky, Hans J. Schlitt, Edward K. Geissler, Rainer Spang, Sebastian Haferkamp, James A. Hutchinson
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-21 (2024)
Abstract Immunological diseases are typically heterogeneous in clinical presentation, severity and response to therapy. Biomarkers of immune diseases often reflect this variability, especially compared to their regulated behaviour in health. This lea
Externí odkaz:
https://doaj.org/article/f1e2e526f7134e5596f23916f7bf3b45
Autor:
Christian Moser, Petra Ruemmele, Sebastian Gehmert, Hedwig Schenk, Marina P Kreutz, Maria E Mycielska, Christina Hackl, Alexander Kroemer, Andreas A Schnitzbauer, Oliver Stoeltzing, Hans J Schlitt, Edward K Geissler, Sven A Lang
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 14, Iss 10, Pp 915-925 (2012)
The prognosis of patients suffering from pancreatic cancer is still poor and novel therapeutic options are urgently needed. Recently, the transcription factor signal transducer and activator of transcription 5b (STAT5b) was associated with tumor prog
Externí odkaz:
https://doaj.org/article/0ed9cc9a5766425895d212fc6899a2e6
Autor:
Sabrina E Vinzón, Ilona Braspenning-Wesch, Martin Müller, Edward K Geissler, Ingo Nindl, Hermann-Josef Gröne, Kai Schäfer, Frank Rösl
Publikováno v:
PLoS Pathogens, Vol 10, Iss 2, p e1003924 (2014)
Certain cutaneous human papillomaviruses (HPVs), which are ubiquitous and acquired early during childhood, can cause a variety of skin tumors and are likely involved in the development of non-melanoma skin cancer, especially in immunosuppressed patie
Externí odkaz:
https://doaj.org/article/cd32d9bcacde41afa70e7fd4cc675cfb
Autor:
Christiane Broichhausen, Paloma Riquelme, Norbert Ahrens, Anja K Wege, Gudrun E Koehl, Hans J Schlitt, Bernhard Banas, Fred Fändrich, Edward K Geissler, James A Hutchinson
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 1, Iss C (2014)
A new cell-based medicinal product containing human regulatory macrophages, known as Mreg_UKR, has been developed and conforms to expectations of a therapeutic drug. Here, Mreg_UKR was subjected to pharmacokinetic, safety pharmacology, and toxicologi
Externí odkaz:
https://doaj.org/article/4d6ed0972d8c47da818a90fe9ed5644f
Autor:
Florian Bitterer, Paul Kupke, Akinbami Adenugba, Katja Evert, Gunther Glehr, Paloma Riquelme, Lena Scheibert, Giulia Preverin, Christina Böhm, Matthias Hornung, Hans J. Schlitt, Jürgen J. Wenzel, Edward K. Geissler, Niloufar Safinia, James A. Hutchinson, Jens M. Werner
Publikováno v:
EBioMedicine, Vol 104, Iss , Pp 105184- (2024)
Summary: Background: The increasing prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) incurs substantial morbidity, mortality and healthcare costs. Detection and clinical intervention at early stages of disease improves p
Externí odkaz:
https://doaj.org/article/8d3e4caeb8a74cc7af32f4f9594e9f84
Autor:
Paul Kupke, Johanna Brucker, Jochen M. Wettengel, Ulrike Protzer, Jürgen J. Wenzel, Hans J. Schlitt, Edward K. Geissler, Jens M. Werner
Publikováno v:
Viruses, Vol 16, Iss 5, p 741 (2024)
Hepatitis B virus (HBV) is a major driver of chronic hepatic inflammation, which regularly leads to liver cirrhosis or hepatocellular carcinoma. Immediate innate immune cell response is crucial for the rapid clearance of the infection. Here, natural
Externí odkaz:
https://doaj.org/article/08541a82fe7e490ab7eec775e3bc8885
Autor:
Jordi Yang Zhou, Dominik Eder, Florian Weber, Philipp Heumann, Katharina Kronenberg, Jens M. Werner, Edward K. Geissler, Hans J. Schlitt, James A. Hutchinson, Florian Bitterer
Publikováno v:
Frontiers in Transplantation, Vol 2 (2023)
BackgroundThe approval of Atezolizumab / Bevacizumab therapy (Atezo/Bev) in 2020 opened up a promising new treatment option for patients with end-stage hepatocellular carcinoma (HCC). However, liver transplant (LTx) patients with HCC are still denied
Externí odkaz:
https://doaj.org/article/f62aab5a93d84130a02b902ad9f3715e
Autor:
Edward K. Geissler, PhD, Günter Kirste, MD, Maureen O. Meade, MD, Jeremy R. Chapman, AC, MD, FRACP
Publikováno v:
Transplantation Direct, Vol 9, Iss 5, p e1481 (2023)
Externí odkaz:
https://doaj.org/article/89b1c5fb169d48c59ead48bb5d6f15ad
Autor:
Gunther Glehr, Paloma Riquelme, Jordi Yang Zhou, Laura Cordero, Hannah-Lou Schilling, Michael Kapinsky, Hans J. Schlitt, Edward K. Geissler, Ralph Burkhardt, Barbara Schmidt, Sebastian Haferkamp, James A. Hutchinson, Katharina Kronenberg
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Immune checkpoint inhibitors have revolutionized treatment of advanced melanoma, but commonly cause serious immune-mediated complications. The clinical ambition of reserving more aggressive therapies for patients least likely to experience immune-rel
Externí odkaz:
https://doaj.org/article/19281e5642da4d8289df85c0b98becbd
Autor:
Jordi Yang Zhou, Jens M. Werner, Gunther Glehr, Edward K. Geissler, James A. Hutchinson, Katharina Kronenberg
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
BackgroundSteatotic livers are more prone to rejection, but are often transplanted owing to the shortage of available organs. Type II NKT (T2NKT) cells are liver-resident lymphocytes that react to lipids presented by CD1d. The role of T2NKT cells in
Externí odkaz:
https://doaj.org/article/6ac725fa8c6a4f2492025c2c655286af